You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Leber Hereditary Optic Neuropathy Therapy – Who Should Be Treated and How?

  • Authors: Patrick Yu-Wai Man, BMedSci, MBBS, PhD, FRCPath, FRCOphth; Thomas Klopstock, MD, FEAN
  • CPD Released: 5/9/2022
  • Valid for credit through: 5/9/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for neurologists and ophthalmologists.

The goal of this activity is that learners will be better able to disseminate clinical trial data on bilateral treatment with LHON gene therapy and interpret outcomes for clinical practice, including explaining the effects in the sham eye from previous trials.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • LHON gene therapy approach
    • Latest clinical trial data for LHON gene therapy


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Patrick Yu-Wai Man, BMedSci, MBBS, PhD, FRCPath, FRCOphth

    Department of Clinical Neurosciences
    University of Cambridge 
    Cambridge Eye Unit 
    Addenbrooke’s Hospital 
    Cambridge, United Kingdom
    NIHR Biomedical Research Centre at Moorfields
    Eye Hospital and UCL Institute of Ophthalmology 
    London, United Kingdom

    Disclosures

    Consultant or advisor for: Chiesi; GenSight Biologics; PYC Therapeutics; Santhera Pharmaceuticals; Stoke Therapeutics; Transine Therapeutics

  • Thomas Klopstock, MD, FEAN

    Professor of Neurology
    Friedrich-Baur-Institute
    Department of Neurology
    LMU Klinikum
    Ludwig-Maximilians-Universität
    Munich, Germany

    Disclosures

    Consultant or advisor for: Chiesi
    Speaker or member of speakers bureau for: Chiesi; GenSight Biologics
    Research funding from: Chiesi; GenSight Biologics; Santhera Pharmaceuticals

Editors

  • Katherine Carpenter, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Advisor or consultant for: Eisai, GW Pharmaceuticals 

  • Maya Khalaf, MSc

    Associate Medical Education Director, WebMD Global, LLC 

    Disclosures

    Disclosure: Maya Khalaf, MSc, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Leber Hereditary Optic Neuropathy Therapy – Who Should Be Treated and How?

Authors: Patrick Yu-Wai Man, BMedSci, MBBS, PhD, FRCPath, FRCOphth; Thomas Klopstock, MD, FEANFaculty and Disclosures

CPD Released: 5/9/2022

Valid for credit through: 5/9/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to disseminate clinical trial data on bilateral treatment with LHON gene therapy and interpret outcomes for clinical practice, including explaining the effects in the sham eye from previous trials.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.